Sökning: onr:"swepub:oai:DiVA.org:uu-419066" >
Quantifying and Des...
Quantifying and Describing the Natural History and Costs of Alzheimer's Disease and Effects of Hypothetical Interventions
-
- Wimo, Anders (författare)
- Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning, Gävleborg,Karolinska Inst, Care Sci & Soc, Div Neurogeriatr, Dept Neurobiol, Stockholm, Sweden.;
-
- Handels, Ron (författare)
- Karolinska Institutet
-
- Winblad, Bengt (författare)
- Karolinska Institutet
-
visa fler...
-
- Black, Christopher M. (författare)
- Merck & Co Inc, Ctr Observat & Real World Evidence CORE, Kenilworth, NJ USA.
-
- Johansson, Gunilla (författare)
- Karolinska Institutet
-
- Salomonsson, Stina (författare)
- Merck Sharp & Dohme Ltd, Ctr Observat & Real World Evidence CORE, Stockholm, Sweden.
-
- Eriksdotter, Maria (författare)
- Karolinska Institutet
-
- Khandker, Rezaul K. (författare)
- Merck & Co Inc, Ctr Observat & Real World Evidence CORE, Kenilworth, NJ USA.
-
visa färre...
-
(creator_code:org_t)
- IOS PRESS, 2020
- 2020
- Engelska.
-
Ingår i: Journal of Alzheimer's Disease. - : IOS PRESS. - 1387-2877 .- 1875-8908. ; 75:3, s. 891-902
- Relaterad länk:
-
https://doi.org/10.3...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.3...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: A long-term horizon is necessary when the socioeconomic consequences and the potential effects of interventions in Alzheimer's disease (AD) are estimated. Objectives: To illustrate the potential societal costs of AD across the disease continuum and to illustrate the potential cost-effectiveness of a hypothetical intervention with disease modifying treatment (DMT). Methods: Based on the Swedish dementia registry, a Markov model was used to simulate a virtual cohort of 100,000 people with mild cognitive impairment (MCI) due to AD (AD-MCI) in Sweden for 40 years starting at the age of 60. A simulated hypothetical intervention assumed a 25% reduction in progression rate during AD-MCI and mild AD-dementia. A comprehensive set of sensitivity analyses was included. Results: The cumulative risk to develop dementia was 96%. The mean simulated survival was 19.0 years. The net present value for a person year with dementia was 252,843 SEK (about 29,500 US$). The cost effectiveness model illustrated how the hypothetical scenario of a 25% reduction in progression to AD-dementia would require 41 AD-MCI patients to be treated to prevent one case of AD-dementia (2,447 avoided AD-dementia cases of 100,000 with AD-MCI). Most scenarios illustrated hypothetical cost effectiveness (based on a willingness to pay level of 600,000 SEK (70,000 US$) per gained QALY), but not cost savings. Discussion: Lifetime societal costs of AD are substantial. A future DMT may be potentially cost-effective given assumed treatment effects and costs, but cost savings are unlikely.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Nyckelord
- Alzheimer's disease
- cost analysis
- cost effectiveness
- costs
- dementia
- disease-modifying treatment
- economics
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas